Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Globe and Mail, The
VANCOUVER, BC Jan. 26, 2026 /CNW/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030 [1] , driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year [2] is now making it much easier to build these advanced platforms, clearing a path for companies that can treat diseases internally without the harsh side effects of traditional drugs. This regulatory shift positions Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASAQ: MNKD), Vertex Pharmaceuticals (NASDAQ: VRTX), Fate Therapeutics (NASDAQ: FATE), and Ardelyx (NADSAQ: ARDX) at the center of a massive transformation in chronic healthcare. Read more at newswire.ca This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]Seeking Alpha
- Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy [Yahoo! Finance]Yahoo! Finance
- MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyGlobeNewswire
MNKD
Earnings
- 11/5/25 - Beat
MNKD
Sec Filings
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- 12/29/25 - Form 4
- MNKD's page on the SEC website